Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05371964 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by Geron Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 8
- Study locations
NCT05371964: Recruiting Phase 1 study of Myelofibrosis, sponsored by Geron Corporation.
NCT05371964 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Geron Corporation. The registered enrollment target is 36 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05371964, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Geron Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Imetelstat sodium
Study Locations (8)
California
- City of Hope - Duarte
- City of Hope - Irvine
Florida
- University of Miami - Coral Gables
- H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa
Texas
- Texas Oncology - Denison
- Texas Oncology - Tyler
New York
- Icahn School of Medicine at Mount Sinai - New York
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What NCT05371964 shows while recruiting
NCT05371964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT05371964 lists 8 locations in 5 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT05371964 about?
NCT05371964 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis". The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolit...
What is the current status of trial NCT05371964?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-05-04. Estimated completion is 2028-08.
What conditions does trial NCT05371964 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05371964?
The interventions under investigation include: Ruxolitinib (DRUG), Imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT05371964?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05371964 being conducted?
This trial has 8 study locations across California, Florida, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05371964's enrollment target sits among peer trials
36 37th of 61 higher than 25 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI